GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

MTPA, maker of ALS treatment Radicava, has opened up its care locator database to help patients to find healthcare and infusion centers.

Days after ICER called out Spravato for being too costly, developer J&J unveiled its own analysis based on a cost-per-remitter model, arguing the opposite.

Merck & Co.'s Fosamax fight has lasted for years—and now, thanks to a U.S. Supreme Court ruling Monday, Merck gets yet another chance to press its…

Mallinckrodt’s Acthar Gel has seen its share of lawsuits, but the company was happy to launch another—this time to defend its Medicaid business.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.

Now well on its way to becoming a multiproduct company, Seattle Genetics has decided the time is right to bring in its first chief commercial officer.

Right now, Roche’s Tecentriq is the only I-O drug approved in triple negative breast cancer. And it looks like it’ll stay that way for awhile.

Innovation challenges continue to proliferate in the pharma industry, and Celgene is seeking crowdsourced solutions for multiple sclerosis patients.